Involvement of S100A8 and S100A9 in nonischaemic cardiomyopathy

Abstract

The heterodimeric complex of S100 calcium binding proteins A8 and A9 (S100A8/A9, also known as Calprotectin) is constitutively expressed in myeloid neutrophils and monocytes and plays a role in the modulation of the inflammatory response and cytoskeleton rearrangement. Recently, S100A8/A9 complex has garnered significant attention as a critical alarmin involved in regulating the pathogenesis of various inflammatory cardiovascular diseases, particularly nonischaemic cardiomyopathy (NICM). Furthermore, S100A8/A9 is reportedly associated with the pathophysiological processes of myocardial ischaemia‒reperfusion injury and has also been recognised as a predictor and a potentialmediator of heart failure caused by acutemyocardial infarction. Recent studies have attempted to provide a comprehensive and detailed overview of the involvement of the S100A8/A9 protein in NICM, covering topics such as hypertrophicmyocardial remodelling, septic and dilated cardiomyopathy,myocarditis, chemotherapeutic cardiotoxicity, senescent cardiac dysfunction and cardiac allograft rejection. Ultimately, we aimed to evaluate the application of S100A8/A9 as promising biomarkers and therapeutic strategies for the prediction, prevention and treatment of NICM.

Keywords

biomarker / inflammation / nonischaemic cardiomyopathy / S100A8/A9 / therapeutic strategy

References

[1] ChenDX, LuCH, NaN, YinRX, HuangF. Endothelial progenitor cell-derived extracellular vesicles: the world of potential prospects for the treatment of cardiovascular diseases. Cell Biosci. 2024;14:72.

[2] RothGA, MensahGA, JohnsonCO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019:update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982-3021.

[3] AnderssonC, VasanRS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15:230-240.

[4] RomashkoM, Schragenheim J, AbrahamNG, McClungJA. Epoxyeicosatrienoic acid as therapy for diabetic and ischemic cardiomyopathy. Trends Pharmacol Sci. 2016;37:945-962.

[5] VrtovecB. Cell therapy for nonischemic cardiomyopathy: current status and future perspectives. Circ Res. 2018;122:28-30.

[6] JiaY, ZhangRN, LiYJ, GuoBY, WangJL, Liu SY. Bioinformatics analysis and identification of potential key genes and pathways in the pathogenesis of nonischemic cardiomyopathy. Medicine. 2024;103:e37898.

[7] MirzaKK, Szymanski MK, SchmidtT, et al. Prognostic value of peak oxygen uptake in patients supported with left ventricular assist devices (PRO-VAD). JACC Heart Fail. 2021;9:758-767.

[8] RathiS, Deedwania PC. The epidemiology and pathophysiology of heart failure. Med Clin North Am. 2012;96:881-890.

[9] KadakiaRS, LinkMS, DominicP, Morin DP. Sudden cardiac death in nonischemic cardiomyopathy. Prog Cardiovasc Dis. 2019;62:235-241.

[10] GanesanAN, GuntonJ, NuciforaG, McGavigan AD, SelvanayagamJB. Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol. 2018;254:230-237.

[11] SunY, XuH, GaoW, et al. S100a8/A9 proteins: critical regulators of inflammation in cardiovascular diseases. Front Cardiovasc Med. 2024;11:1394137.

[12] BaiB, XuY, ChenH. Pathogenic roles of neutrophil-derived alarmins (S100A8/A9) in heart failure: from molecular mechanisms to therapeutic insights. Br J Pharmacol. 2023;180:573-588.

[13] AdamoL, Rocha-Resende C, PrabhuSD, MannDL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17:269-285.

[14] Silvestre-RoigC, Braster Q, Ortega-GomezA, SoehnleinO. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17:327-340.

[15] JohnsonJ, Jaggers RM, GopalkrishnaS, et al. Oxidative stress in neutrophils: implications for diabetic cardiovascular complications. Antioxid Redox Signaling. 2022;36:652-666.

[16] BoralkarKA, Kobayashi Y, AmsallemM, et al. Value of neutrophil to lymphocyte ratio and its trajectory in patients hospitalized with acute heart failure and preserved ejection fraction. Am J Cardiol. 2020;125:229-235.

[17] MaJ, LiY, LiP, et al. S100A8/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure. Nat Commun. 2024;15:2701.

[18] SprattDE, BarberKR, MarlattNM, et al. A subset of calcium-binding S100 proteins show preferential heterodimerization. FEBS J. 2019;286:1859-1876.

[19] DorinJR, EmslieE, van HeyningenV. Related calcium-binding proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3. Genomics. 1990;8:420-426.

[20] PasseyRJ, Williams E, LichanskaAM, et al. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol. 1999;163:2209-2216.

[21] HobbsJA, MayR, TanousisK, et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol Cell Biol. 2003;23:2564-2576.

[22] ManitzMP, HorstB, SeeligerS, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol. 2003;23:1034-1043.

[23] LiY, ChenB, YangX, et al. S100a8/a9 signaling causes mitochondrial dysfunction and cardiomyocyte death in response to ischemic/reperfusion injury. Circulation. 2019;140:751-764.

[24] CharkhizadehS, ImaniM, GheibiN, Shabaani F, NikpajouhA, RezvanyMR. In vitro inhibitory effect of recombinant human calprotectin on nalm6 leukemia cell line. Anticancer Agents Med Chem. 2020;20:951-962.

[25] HessianPA, Edgeworth J, HoggN. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukocyte Biol. 1993;53:197-204.

[26] AverillMM, Kerkhoff C, BornfeldtKE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2012;32:223-229.

[27] EhrchenJM, Sunderkötter C, FoellD, VoglT, RothJ. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukocyte Biol. 2009;86:557-566.

[28] YenT, Harrison CA, DeveryJM, et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood. 1997;90:4812-4821.

[29] YaoD, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59:249-255.

[30] Landers-RamosRQ, SappRM, VandeWaterE, et al. Investigating the extremes of the continuum of paracrine functions in CD34-/CD31+ CACs across diverse populations. Am J Physiol Heart Circ Physiol. 2017;312:H162.

[31] McCormickMM, RahimiF, BobryshevYV, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280:41521-41529.

[32] GrimbaldestonMA, GeczyCL, TedlaN, Finlay-Jones JJ, HartPH. S100A8 induction in keratinocytes by ultraviolet A irradiation is dependent on reactive oxygen intermediates. J Invest Dermatol. 2003;121:1168-1174.

[33] InabaH, Hokamura K, NakanoK, et al. Upregulation of S100 calcium-binding protein A9 is required for induction of smooth muscle cell proliferation by a periodontal pathogen. FEBS Lett. 2009;583:128-134.

[34] RahimiF, HsuK, EndohY, Geczy CL. FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS J. 2005;272:2811-2827.

[35] IngersollMA, Spanbroek R, LottazC, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010;115:e10-9.

[36] WuF, ZhangYT, TengF, Li HH, GuoSB. S100a8/a9 contributes to sepsis-induced cardiomyopathy by activating ERK1/2-Drp1-mediated mitochondrial fission and respiratory dysfunction. Int Immunopharmacol. 2023;115:109716.

[37] CotoiOS, Dunér P, KoN, et al. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 2014;34:202-210.

[38] LeukertN, SorgC, RothJ. Molecular basis of the complex formation between the two calcium-binding proteins S100A8 (MRP8) and S100A9 (MRP14). Biol Chem. 2005;386:429-434.

[39] LeukertN, VoglT, StrupatK, Reichelt R, SorgC, RothJ. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol. 2006;359:961-972.

[40] MarinkovićG, Grauen Larsen H, YndigegnT, et al. Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. Eur Heart J. 2019;40:2713-2723.

[41] DonatoR. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540-551.

[42] VoglT, Leukert N, BarczykK, StrupatK, RothJ. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. Biochim Biophys Acta. 2006;1763:1298-1306.

[43] RammesA, RothJ, GoebelerM, Klempt M, HartmannM, SorgC. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272:9496-9502.

[44] SteinbakkM, Naess-Andresen CF, LingaasE, DaleI, Brandtzaeg P, FagerholMK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763-765.

[45] LackmannM, Cornish CJ, SimpsonRJ, MoritzRL, GeczyCL. Purification and structural analysis of a murine chemotactic cytokine (CP-10) with sequence homology to S100 proteins. J Biol Chem. 1992;267:7499-7504.

[46] TardifMR, Chapeton-Montes JA, PosvandzicA, PagéN, Gilbert C, TessierPA. Secretion of S100A8, S100A9, and S100A12 by neutrophils involves reactive oxygen species and potassium efflux. J Immunol Res. 2015;2015:296149.

[47] BrinkmannV, Reichard U, GoosmannC, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535.

[48] DoussièreJ, Bouzidi F, VignaisPV. A phenylarsine oxide-binding protein of neutrophil cytosol, which belongs to the S100 family, potentiates NADPH oxidase activation. Biochem Biophys Res Commun. 2001;285:1317-1320.

[49] DoussiereJ, Bouzidi F, VignaisPV. The S100A8/A9 protein as a partner for the cytosolic factors of NADPH oxidase activation in neutrophils. Eur J Biochem. 2002;269:3246-3255.

[50] VoglT, LudwigS, GoebelerM, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-4268.

[51] EhlermannP, EggersK, BierhausA, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006;5:6.

[52] BoydJH, KanB, RobertsH, Wang Y, WalleyKR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008;102:1239-1246.

[53] VoglT, Tenbrock K, LudwigS, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042-1049.

[54] KawakamiR, Katsuki S, TraversR, et al. S100A9–RAGE axis accelerates formation of macrophage-mediated extracellular vesicle microcalcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2020;40:1838-1853.

[55] SunahoriK, Yamamura M, YamanaJ, et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R69.

[56] FasslSK, Austermann J, PapantonopoulouO, et al. Transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8. J Immunol. 2015;194:575-583.

[57] PetersenB, WolfM, AustermannJ, et al. The alarmin Mrp8/14 as regulator of the adaptive immune response during allergic contact dermatitis. EMBO J. 2013;32:100-111.

[58] FrangogiannisNG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255-265.

[59] KeceliG, GuptaA, SourdonJ, et al. Mitochondrial creatine kinase attenuates pathologic remodeling in heart failure. Circ Res. 2022;130:741-759.

[60] TakanoAPC, MunhozCD, MoriscotAS, Gupta S, Barreto-ChavesMLM. S100A8/MYD88/NF-κB: a novel pathway involved in cardiomyocyte hypertrophy driven by thyroid hormone. J Mol Med. 2017;95:671-682.

[61] YanX, WuL, GaoM, YangP, YangJ, Deng Y. Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway. Exp Therap Med. 2022;23:292.

[62] YuanYP, ShenZY, TengT, et al. S100a8/9 (S100 calcium binding protein a8/9) promotes cardiac hypertrophy via upregulation of FGF23 (fibroblast growth factor 23) in mice. J Am Heart Assoc. 2024;13:e028006.

[63] WeiX, WuB, ZhaoJ, et al. Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of S100A8/A9. Circulation. 2015;131:1506-1517. discussion 1517.

[64] MaL, ShiH, LiY, et al. Hypertrophic preconditioning attenuates myocardial ischemia/reperfusion injury through the deacetylation of isocitrate dehydrogenase 2. Sci Bull. 2021;66:2099-2114.

[65] LiuJ, ChenX, ZengL, et al. Targeting S100A9 prevents β-adrenergic activation-induced cardiac injury. Inflammation. 2024;47:789-806.

[66] WuY, LiY, ZhangC, et al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-Induced cardiac inflammation and injury. Hypertension. 2014;63:1241-1250.

[67] FengL, LiG, AnJ, et al. Exercise training protects against heart failure via expansion of myeloid-derived suppressor cells through regulating IL-10/STAT3/S100A9 pathway. Circulation Heart Failure. 2022;15:e008550.

[68] SingerM, Deutschman CS, SeymourCW, et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-810.

[69] WangQ, LongG, LuoH, et al. S100A8/A9:an emerging player in sepsis and sepsis-induced organ injury. Biomed Pharmacother. 2023;168:115674.

[70] RavikumarN, SayedMA, PoonsuphCJ, Sehgal R, ShirkeMM, HarkyA. Septic cardiomyopathy: from basics to management choices. Curr Probl Cardiol. 2021;46:100767.

[71] ParkerMM, Shelhamer JH, BacharachSL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-490.

[72] JakobssonG, Papareddy P, AnderssonH, et al. Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Crit Care. 2023;27:374.

[73] TousifS, SinghAP, UmbarkarP, et al. Ponatinib drives cardiotoxicity by S100A8/A9-NLRP3-IL-1β mediated inflammation. Circ Res. 2023;132:267-289.

[74] LiP, ChenXR, XuF, et al. Alamandine attenuates sepsis-associated cardiac dysfunction via inhibiting MAPKs signaling pathways. Life Sci. 2018;206:106-116.

[75] LuF, HuF, QiuB, ZouH, XuJ. Identification of novel biomarkers in septic cardiomyopathy via integrated bioinformatics analysis and experimental validation. Front Genet. 2022;13:929293.

[76] Van LinthoutS, Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy. Curr Opin Cardiol. 2018;33:325-333.

[77] MüllerI, VoglT, PappritzK, et al. Pathogenic role of the damage-associated molecular patterns S100A8 and S100A9 in coxsackievirus B3-induced myocarditis. Circ Heart Fail. 2017;10:e004125.

[78] KumarN, Pestrak MJ, WuQ, et al. Pseudomonas aeruginosa pulmonary infection results in S100A8/A9-dependent cardiac dysfunction. PLoS Pathog. 2023;19:e1011573.

[79] OtsukaK, Terasaki F, IkemotoM, et al. Suppression of inflammation in rat autoimmune myocarditis by S100A8/A9 through modulation of the proinflammatory cytokine network. Eur J Heart Fail. 2009;11:229-237.

[80] CaforioAL, Pankuweit S, ArbustiniE, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-2648. 2648a-2648d.

[81] MüllerI, VoglT, KühlU, et al. Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail. 2020;7:1442-1451.

[82] YuY, ShiH, WangY, Yu Y, ChenR. A pilot study of S100A4, S100A8/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis? ESC Heart Fail. 2024;11:503-512.

[83] ZhuH, HeM, WangYL, et al. Low-intensity pulsed ultrasound alleviates doxorubicin-induced cardiotoxicity via inhibition of S100a8/a9-mediated cardiac recruitment of neutrophils. Bioeng Transl Med. 2023;8:e10570.

[84] PeiXM, TamBT, SinTK, et al. S100A8 and S100A9 are associated with doxorubicin-induced cardiotoxicity in the heart of diabetic mice. Front Physiol. 2016;7:334.

[85] HuangKM, ThomasMZ, MagdyT, et al. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Nat Acad Sci U S A. 2021;118:e2020168118.

[86] CrimminsEM, ShimH, ZhangYS, Kim JK. Differences between men and women in mortality and the health dimensions of the morbidity process. Clin Chem. 2019;65:135-145.

[87] TriposkiadisF, Xanthopoulos A, ButlerJ. Cardiovascular aging and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019;74:804-813.

[88] LoffredoFS, Nikolova AP, PancoastJR, LeeRT. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97-107.

[89] SunSN, NiSH, LiY, et al. G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence. Cell Death Dis. 2021;12:594.

[90] BonoraBM, PalanoMT, TestaG, et al. Hematopoietic progenitor cell liabilities and alarmins S100A8/A9-related inflammaging associate with frailty and predict poor cardiovascular outcomes in older adults. Aging Cell. 2022;21:e13545.

[91] MuesB, BrisseB, ZwadloG, Themann H, BenderF, SorgC. Phenotyping of macrophages with monoclonal antibodies in endomyocardial biopsies as a new approach to diagnosis of myocarditis. Eur Heart J. 1990;11:619-627.

[92] BurkhardtK, Radespiel-Tröger M, RupprechtHD, et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J Am Soc Nephrol. 2001;12:1947-1957.

[93] ShimizuK, LibbyP, RochaVZ, et al. Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection. Circulation. 2011;124:2920-2932.

[94] ShahzadK, Cadeiras M, MemonS, et al. Gene expression signatures of peripheral blood mononuclear cells during the early post-transplant period in patients developing cardiac allograft vasculopathy. J Transplant. 2010;2010:719696.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.